Source: Pharamceutical Technology

F-star: FS-102 by F-star Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

FS-102 is under clinical development by F-star Therapeutics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.

Read full article »
F-star's Competitors | F-star's News | F-star's Financials
Stay up-to-date with the latest news on F-star
Annual Revenue
$5.0-25M
Employees
25-100
Eliot Forster's photo - CEO of F-star

CEO

Eliot Forster

CEO Approval Rating

88/100

Read more
Stay up-to-date with the latest news on F-star